resist
apoptosi
often
result
overexpress
antiapoptot
protein
common
cancer
remain
uncertain
whether
defect
apoptosi
essenti
tumour
mainten
letai
et
al
investig
idea
use
mice
develop
leukaemia
overexpress
key
antiapoptot
protein
bcell
could
condit
turn
elimin
rapidli
induc
apoptosi
leukaemia
remiss
provid
support
potenti
anticanc
drug
target
suggest
apoptot
defect
elimin
inher
death
signal
would
kill
cancer
cell
nisinlipid
ii
complex
reveal
pyrophosph
cage
provid
blueprint
novel
antibiot
hsu
et
al
natur
struct
mol
biol
famili
lanthioninecontain
antibiot
nisin
member
could
promis
candid
allevi
grow
problem
antibiot
resist
nisin
act
bind
lipid
ii
essenti
precursor
cellwal
synthesi
hsu
colleagu
report
solut
structur
complex
nisin
lipid
ii
indic
possibl
structurebas
design
novel
antibiot
resist
apoptosi
often
result
overexpress
antiapoptot
protein
common
cancer
remain
uncertain
whether
defect
apoptosi
essenti
tumour
mainten
letai
et
al
investig
idea
use
mice
develop
leukaemia
overexpress
key
antiapoptot
protein
bcell
could
condit
turn
elimin
rapidli
induc
apoptosi
leukaemia
remiss
provid
support
potenti
anticanc
drug
target
suggest
apoptot
defect
elimin
inher
death
signal
would
kill
cancer
cell
nisinlipid
ii
complex
reveal
pyrophosph
cage
provid
blueprint
novel
antibiot
hsu
et
al
natur
struct
mol
biol
famili
lanthioninecontain
antibiot
nisin
member
could
promis
candid
allevi
grow
problem
antibiot
resist
nisin
act
bind
lipid
ii
essenti
precursor
cellwal
synthesi
hsu
colleagu
report
solut
structur
complex
nisin
lipid
ii
indic
possibl
structurebas
design
novel
antibiot
identif
novel
smallmolecul
inhibitor
sever
acut
respiratori
syndromeassoci
coronaviru
chemic
genet
kao
r
et
al
chem
biol
kao
et
al
screen
structur
divers
compound
capac
protect
cell
cytopath
effect
induc
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
around
compound
found
strong
antivir
activ
sever
character
found
target
specif
protein
involv
viral
pathogenesi
compound
repres
possibl
lead
drug
develop
possibl
novel
therapi
diabet
cellperm
jnkinhibitori
peptid
kaneto
h
et
al
natur
med
activ
cjun
ntermin
known
abnorm
elev
sever
tissu
diabet
state
activ
pathway
interfer
insulin
action
kaneto
et
al
treat
diabet
mice
cellperm
jnkinhibitori
peptid
deriv
jnkbind
domain
jnkinteract
found
markedli
improv
insulin
resist
amelior
glucos
toler
indic
jnk
pathway
key
role
diabet
understand
mechan
antagon
therapeut
necessari
clearli
map
structur
basi
integrin
activ
much
specul
integrin
becom
activ
crystal
structur
inact
integrin
avail
write
natur
springer
cowork
report
atom
detail
first
crystal
structur
integrin
activ
form
integrin
heterodim
form
subunit
contain
extracellular
domain
singl
transmembran
domain
short
cytoplasm
domain
extracellular
domain
includ
headpiec
bind
integrin
ligand
tailpiec
connect
transmembran
domain
integrin
activ
mark
structur
chang
occur
spatial
relationship
integrin
domain
lead
highaffin
ligand
bind
integrin
iib
resid
membran
platelet
import
activ
clot
process
follow
vascular
injuri
also
involv
patholog
thrombosi
platelet
signal
initi
respons
vascular
injuri
caus
chang
cytoplasm
domain
iib
transmit
conform
chang
extracellular
domain
iib
lead
highaffin
bind
fibrinogen
give
rise
platelet
aggreg
springer
cowork
describ
detail
conform
chang
iib
transfer
domain
use
two
antagonist
tirofiban
eptifibatid
design
mimic
fibrinogen
therefor
prevent
ligand
bind
known
effect
treat
prevent
coronari
arteri
thrombosi
crystal
structur
reveal
basi
drug
bind
select
might
aid
drug
develop
target
iib
furthermor
structur
chang
extracellular
domain
identifi
iib
integrin
seem
gener
integrin
knowledg
could
lead
improv
design
integrin
antagonist
rang
diseas
